Baird Maintains Neutral on Quest Diagnostics, Raises Price Target to $255
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $236 to $255.
Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $236 to $255.